What is AVTX's health score?

Avalo Therapeutics, Inc. (AVTX) has a TradeApes health score of 38 out of 100, rated Weak. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is AVTX's estimated fair value?

Based on our 5-year discounted cash flow model, Avalo Therapeutics, Inc.'s estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is AVTX undervalued or overvalued?

Our model currently rates AVTX as Inconclusive. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for AVTX... Refresh in a moment for the full analysis.

Avalo Therapeutics, Inc. (AVTX)

Healthcare Inconclusive inconclusive weak

$13.61

Updated: 2026-06-05

TradeApes Score

Financial Strength

45 Mixed

Operating Trend

40 Weak

Relative Value

15 Stressed

Capital Allocation

30 Weak

Risk

80 Strong

Key Findings

+ Strong liquidity — current assets more than 2× current liabilities

Unlock Full Report →

− Historically expensive — EV/EBITDA in top 20% of its 5-year range

Unlock Full Report →

4 free score cards remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.